Flavopiridol: where do we stand in chronic lymphocytic leukemia?
Lin
T S
TS
Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA.
Porcu
P
P
D017209:Apoptosis / Q000187:drug effects; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D005419:Flavonoids / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D019001:Nitric Oxide Synthase / Q000096:biosynthesis; D052247:Nitric Oxide Synthase Type II; D010880:Piperidines / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics
D005419:Flavonoids; D010880:Piperidines; D016159:Tumor Suppressor Protein p53; C077990:alvocidib; C496319:NOS2 protein, human; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C505407:CASP3 protein, human; D053148:Caspase 3; D020169:Caspases